Lecanemab: digiDEM Bavaria calculates initial estimates for Germany

The new Alzheimer's drug Lecanemab is raising great hopes for people with dementia and their caregivers. Very recently, a panel of experts from the European Medicines Agency (EMA) recommended the new active ingredient for treatment – subject to strict conditions. But which patient groups meet the requirements for treatment with Lecanemab? This...

digiDEM Bavaria SPOTLIGHT_07: New Medications for Dementia - A „Breakthrough with Side Effects“

In recent weeks, we have informed you in several parts of our special newsletter SCHLAGLICHT – Medications for Dementia about new dementia drugs and challenges in everyday care. You can reread all published issues at any time in our digiDEM Bavaria newsletter archive: https://digidem-bayern.de/newsletter-archiv/. In the seventh and final issue of our special newsletter SCHLAGLICHT – Medications for Dementia, Michael...